The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Moving toward a cure for cHL without chemotherapy: results of a clinical trial
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses the potential for treating patients with classical Hodgkin lymphoma (cHL) using a chemotherapy-free approach. The results of a small clinical trial conducted in older patients (aged over 60) with cHL who were ineligible for intensive chemotherapy demonstrated that around half of patients achieved durable remissions at a median follow-up of four years when treated with brentuximab vedotin plus nivolumab. Dr Lynch highlights that this may pave the way for chemotherapy-free treatment approaches, reducing the treatment burden of patients with the disease. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: TG Therapeutics, Incyte, Bayer, Cyteir, Genentech, SeaGen, Rapt, Merck, Janssen; Consultancy/Honoraria: SeaGen, Foresight Diagnostics, Abbvie, Janssen, Merck.
